VAL

Valirx PLC

Health Care First-pass screen £2.08m

290/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 35

Valuation 25% 30

Downside protection 15% 25

First-pass take

Early-stage cancer biotech with zero AI exposure; Inaphaea service business showed first traction (£50k revenue 2024) but company burns £1.6m annually. Going concern flagged by auditors; runway <12m without fresh funding. No valuation data provided.

Flags

loss-makinggoing-concernpre-revenuehigh-burnno-valuation-datacapital-intensiveno-ai-strategy